In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients

Cancer Letters

Volumn 162, Issue 2, 2001, Pages 193-200

  Jonsson, Elin ^a   Friberg, Lena E ^b   Karlsson, Mats O ^b   Hassan, Saadia B ^a   Nygren, Peter ^a   Kristensen, Jörgen ^a,c   Tholander, Bengt ^a   Binderup, Lise ^d   Larsson, Rolf ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Leo Pharmaceuticals   (Sweden)

^d LEO PHARMA A S   (Denmark)

Author keywords

Anticancer drug; Cyanoguanidine; Drug development; Hollow fibre; Primary human tumour cell

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CLADRIBINE; CYANOGUANIDINE N (4 CHLOROPHENOXYHEXYL) N' CYANO N'' 4 PYRIDYLGUANIDINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; PACLITAXEL; PREDNISOLONE; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MALE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RAT; TUMOR CELL; TUMOR CELL CULTURE;

AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CYANIDES; CYTOLOGICAL TECHNIQUES; FEMALE; GUANIDINES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 0035951688     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00661-3     Document Type: Article

References (14)

1. In vivo cultivation of tumor cells in hollow fibers
2. Determination of drug effect on tumor cells, host animal toxicity and drug pharmacokinetics in a hollow-fiber model in rats
3. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumor cells ex vivo and in the clinic
4. Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: Results with 8-chloro-cAMP
5. Antineoplastic drug screening belongs in the laboratory, not in the clinic
6. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo
7. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA)
8. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA)
9. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia
10. Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a bayesian model
11. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures
12. Predictive sensitivity of human cancer cells in vivo using semipermeable polysulfone fibers
13. Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: Implications for anticancer drug screening programs